Personalized pre-surgery treatment for HER2-negative early breast cancer
Part of Cancer clinical trials.
This study tests a treatment plan chosen using lab drug testing on a patient’s tumor (in a dish). It may help improve outcomes for people with early breast cancer that is HER2-negative by matching therapy to what the tumor seems sensitive to.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have invasive breast cancer (not just abnormal cells).
- Your breast cancer tests negative for HER2 (a specific cancer marker).
- Your cancer is early stage, such as T2 or lymph node–positive (not stage IV).
- Your overall health is good enough to be active most of the time (ECOG 0–1).
- Your cancer is not inflammatory breast cancer.
- You do not have severe long-term (chronic) medical problems that could limit treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that is chosen using drug-testing in a lab (to see which medicines may work best) before surgery. It is for people with early-stage HER2-positive breast cancer, aiming to improve outcomes by guiding the right treatment early.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This study tests a personalized approach for early-stage breast cancer that is HER2-positive or triple-negative. The goal is to adjust your treatment based on how well the cancer responds to chemotherapy before surgery, so you get the right amount of radiation therapy—no more, no less.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
Hear when a new HER2-negative Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.